Figure 5. Anti-EGFR-IFNβ restores the cross-presentation ability of DCs.

A) WT B6 mice (n=5/group) were injected subcutaneously with 5×10⁵ B16-EGFR-SIY and treated with 25 μg of anti-EGFR-IFNβ or control Ab on days 14 and 18. Seven days after the last treatment, dLN cells were collected and IFNγ ELISPOT assay was performed without SIY peptide restimulation. B) WT B6 mice (n=5/group) were injected subcutaneously with 5×10⁵ B16-EGFR-SIY and treated with 25 μg of anti-EGFR-IFNβ or control Ab on days 14 and 18. Four days after the last treatment, DCs from dLNs were purified by CD11c⁺ positive selection and incubated with purified naïve 2C T cells with or without SIY peptide restimulation. IFNγ production was measured 2 days later. C) DCs activation markers were also measured by flow cytometry. D) About 40 days after indicated bone marrow chimera reconstitution, mice were injected subcutaneously with 5×10⁵ B16-EGFR-SIY and treated with 25μg of anti-EGFR-IFNβ or control Ig on days 14, 18, and 22. DT or PBS was administrated on the same days as treatment. Tumor growth was measured and compared twice a week. *, p < 0.05 compared with control group. Mean + SEM are shown. One representative experiment of two or three is depicted. See also Figure S4.